EDE Approves RINVOQ as First Oral Treatment for Non-Segmental Vitiligo
Abu dhabi: The Emirates Drug Establishment (EDE) has approved a new therapeutic indication for RINVOQ (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 years and older whose condition requires systemic therapy through me…